



RECEIVED
OCT 17 1995
GROUP 1800

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: §
Donald MORTON §
Rishab K. GUPTA §
David M. EUHUS §
Serial No.: 07/431,533 §
Filed: November 3, 1989 §
For: URINARY TUMOR ASSOCIATED §
ANTIGEN, ANTIGENIC SUB- §
UNITS AND METHODS OF §
DETECTION §

Group Art Unit: 1813


Examiner: H. Sidberry

Atty Dkt.: CADL:002/PAR

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

September 18, 1995
Date


Steven L. Highlander

DECLARATION OF DR. RISHAB GUPTA UNDER 37 CFR §1.132

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Rishab Gupta declare that:

1. I am a U.S. citizen residing at 7118 Costello Ave., Van Nuys, California. Currently,
I am Vice President of Education and Director of Immunodiagnosis at John Wayne Cancer

BEST AVAILABLE COPY

Institute. I have been employed by John Wayne Cancer Institute since July 1, 1991. I am a named inventor of the above-captioned application.

2. Attached to this declaration is a copy of my *curriculum vitae*.

3. It is my understanding that the examiner in charge of the above-captioned application has rejected the UTAA composition claims thereof as anticipated or rendered obvious by Paulie *et al.*, *Cancer Immunol. Immunother.* 17:173-179 (1984).

4. I contacted Dr. Staffan Paulie, first-named author of the Paulie *et al.* paper, and requested samples of antibodies he had used to identify the 92 kD antigen described in the reference. In response, Dr. Paulie provided samples of two antibodies, 7E9 and P7A5, that are directed to the 92 kD antigen. 7E9 is described in the paper and P7A5 was developed from a later fusion.

5. The materials and methods for comparative experiments were as follows:

Two batches of UTAA 90 kD subunit were prepared on March 25, 1993 and on June 29, 1995. These were used as target antigen for Western blots at 5 μ g per lane of an 8-16% gradient SDS-PAGE slab gel (Novax, San Diego). Electrophoresed antigen was transferred to nitrocellulose membrane, washed, blocked and cut into strips. The strips were reacted with the indicated antibodies

at the indicated dilutions according to standard Western blot protocols. Reactivity was determined using goat anti-mouse Ig conjugated to alkaline phosphatase, thereby detecting both IgG and IgM.

6. As can be seen from the attached Western blots, provided as FIG. 1 (Ab dilution 1:100), FIG. 2 and FIG. 3 (Ab dilution 1:500), it is clear that the 90-100 kD UTAA antigen is not recognized by the antibodies provided by Dr. Paulie. Yet these antibodies have been demonstrated to react with the 92 kD antigen by Dr. Paulie. Thus, the 92 kD antigen described in the Paulie *et al.* paper is immunologically unrelated to the antigen being claimed in the above-captioned application.

7. It is my understanding that the examiner in charge of the above-captioned application has questioned the feasibility of "enhancement" of antibody production in human subjects. To address this concern, the attached FIG. 4 shows the enhancement antibody titers in four melanoma patients following administration of UTAA in the form of irradiated melanoma cells. These data demonstrate that administration UTAA can enhance the production of anti-UTAA antibodies over those levels already existing in melanoma patients.

8. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Rishab Gupta

i:\cadl\002\pto\gupta.dec

Figure 1





Figure 1

Figure 2

STRATAGENE EAGLEEYE II 08/07/95 17:16:57

IMAGE SIZE (640 x 480 x 8).
REAL-TIME ACQUIRE.
IMAGE CREATED ON MON AUG 07 17:14:14 1995.




BEST AVAILABLE COPY

Figure 3

STRATASINE EAGLEEYE II 08/07/95 17:05:50

IMAGE SIZE 1640 * 480 * 87.
 REAL-TIME ACQUIRE.
 IMAGE CREATED ON MON AUG 07 17:05:25 1995.



BEST AVAILABLE COPY




Figure 4

July, 1995

CURRICULUM VITAE AND BIBLIOGRAPHY

NAME: RISHAB KUMAR GUPTA

PRESENT TITLE: Vice-President for Educational Affairs and
Director of Immunodiagnosis

ADDRESS: John Wayne Cancer Institute
2200 Santa Monica Blvd.
Santa Monica, California 90404, U.S.A.
Phone: Office (310) 449-5265; FAX (310) 449-5273; Residence (818) 785-1241

PERSONAL DATA: Date of birth: April 18, 1943; Place of birth: India; Married; Two children;
Country of Citizenship: U.S.A.

EDUCATION:

1960-1963	B.Sc. (Hons); G.B. Pant University, Pantnagar, India
1963-1965	M.Sc. (Microbiology); G.B. Pant University, Pantnagar, India
1965-1968	M.S. (Biochemistry); Rutgers University, New Brunswick, N.J., U.S.A
1965-1968	Ph.D. (Microbiology); Rutgers University, New Brunswick, N.J., U.S.A.

SPECIAL TRAINING:

1965	Special summer course in microbiology, School of Basic Sciences, India
1967	Summer trainee at the University of Cincinnati, Department of Microbiology, Cincinnati, Ohio, U.S.A.
1967	Trainee at the Battle Memorial Institute, Richmond, Washington, U.S.A.
1968-1970	Post-doctoral fellowship at UCLA Medical School, Department of Microbiology and Immunology, U.S.A.
1970-1971	Post-doctoral fellowship at Yale University Medical School, Department of Microbiology, U.S.A.
1971-1972	Post-doctoral fellowship at Jules Stein Eye Institute, UCLA School of Medicine, U.S.A.
1973	Annual Survey Course in Immunology of the American Association of Immunologists, Woodshole, MA
1976	Protein Separation by SDS-PAGE, Scripps Research Foundation, La Jolla, Ca
1985	Molecular Immunology Course, University of California, San Francisco, Ca

ACADEMIC APPOINTMENTS:

1991-present	Director of Immunodiagnosis and Vice-president of Education, John Wayne Cancer Institute, Santa Monica, Ca
1991-present	Professor emeritus, Division of Oncology, Department of Surgery, UCLA School of Medicine, Los Angeles, Ca
1985-1991	Professor, Division of Oncology, Department of Surgery, UCLA School of Medicine, Los Angeles, Ca
1981-85	Associate Professor, Division of Oncology, Department of Surgery, UCLA School of Medicine
1979-81	Assistant Professor, Division of Oncology, Department of Surgery, UCLA School of Medicine
1975-82	Microbiologist (WOC), V.A. Medical Center, Sepulveda, CA
1975-79	Associate Research Oncologist, Department of Surgery, UCLA School of Medicine, Los Angeles, CA
1972-75	Assistant Research Oncologist, Department of Surgery, UCLA School of Medicine, Los Angeles, CA
1971-72	Postgraduate Research Microbiologist, Ophthalmic Microbiology, Jules Stein Eye Institute, UCLA
1970-71	Postdoctoral Fellow, Department of Microbiology, School of Medicine, Yale University, New Haven, CT
1968-70	Lecturer, Department of Microbiology and Immunology, UCLA School of Medicine, Los Angeles, CA
1965-68	Research Associate, Department of Biochemistry and Microbiology, Rutgers University, New Brunswick

RESEARCH INTERESTS AND SPECIALTIES:

Tumor Immunology, Immunochemistry, Microbial Physiology, Membrane Transport, Hybridoma techniques, Monoclonal Antibodies, Enzyme Immunoassay (ELISA), Radioimmunoassay, Molecular biology techniques (purification and enrichment of mRNA, preparation of cDNA, gene cloning, PCR, in situ hybridization, T cell receptors and growth factors.

ACADEMIC AWARDS AND HONORS:

1963	University Merit Certificate from G.B. Pant University, India
1963-1965	USAID Traineeship Award
1965-1968	NSF Fellowship at Rutgers
1967	ASM President's Fellowship Award
1969	Sigma Xi-UCLA Chapter
1970-1971	Post-doctoral Fellowship (NRSA) at Yale University
1973	Selected for the Annual Survey Course of AAI
1978	Co-chairman, Tumor Antigens session at the AACR annual meeting
1979	Invited participant in Workshop on Human Tumor Antigens, NIH.
1980	4th Asian Cancer Congress, Bombay, India, invited participant.
1980	Workshop on Tumor Markers, Clinical Ligand Assay Society, Los Angeles, invited faculty
1981	Invited Participant in Workshop on Melanoma Monoclonal Antibodies, NIH.
1981	Workshop on ELISA, Cordia Laboratories, Culver City, invited faculty.
1982	Invited Faculty for Workshop on Practical Aspects of ELISA, Cordia Laboratories.
1983	Invited Faculty for Workshop on Melanoma Immunology, European Soc for Dermatological Res.
1984	Invited participant, 26th Annual Science Writer's Seminar of American Cancer Society.
1985	Invited Speaker at Central Toxicological Research Institute, Lucknow.
1986	Participating Faculty at Hybridoma Techniques Workshop, California State University, Fullerton, Ca
1987	Invited Speaker at the Indian Society of Biological Chemists.
1987	Invited Speaker at the Argentina Society of Immunology and Society of Clinical Invest.
1987	Invited speaker, "Immune Response to Human Melanoma" - Cancer Research Institute.
1988	Ad Hoc Review Member, Clinical Sciences Study Section, National Institute of Health, Bethesda, MD.
1988-1989	Study Section Member, Clinical Sciences, National Institute of Health, Bethesda, MD.
1989	Radioimmunoassay Workshop Faculty, California Polytechnic, Pomona, Ca.
1989-1991	Study Section Member, Immunology, Virology and Pathology, National Institute of Health, Bethesda, MD.
1990-1991	Research Grant Reviewer, Medical Research Council of Canada.
1992-1993	National Reviewer Reserve, NIH, Bethesda, MD.
1993-	Study Section Member, Immunology, Virology and Pathology, National Institute of Health, Bethesda, MD.

TEACHING PARTICIPATION:

Immunology, Immunochemistry, Medical Mycology, General Virology, General Mycology, Biochemistry, General Microbiology, Physiology of Fungi, Medical Mycology Seminars, In-depth laboratory Investigations in Tumor Immunology, Special Research Topics in Immunology, Interactive Teaching for second year medical students.

SCHOLARLY SOCIETY MEMBERSHIP:

American Association for Cancer Research; American Association of Immunologists
 American Society of Clinical Oncology; American Association for Education;
 American Society for Microbiology; Sigma Xi;
 Society for Oncodevelopmental Biology and Medicine;
 American Academy of Microbiology; Clinical Immunology Society

COMMITTEE ASSIGNMENTS:

1978-present	UCLA Mentor program.
1979	Member of Round Table Symposium Committee of the American Academy of Microbiology.
1979-1983	Member of Research Advisory Committee for Advanced Science Training Program.
1980-1982	Member of the Interviewing Committee for the Advanced Science Training Program.
1985-1988	Control and Oversee the Divisional Business office.
1985-1991	Ad hoc member of Promotion Committees Appointed by the Academic Senate.
1991-present	Human Subject Protection Committee at Saint John's Hospital and Health Center.

CERTIFICATION:

Specialist Microbiologist in Medical and Public Health Laboratory

EDITORIAL POSITIONS:

1976-	Reviewer, European Journal of Cancer
1978-	Reviewer, Journal of the National Cancer Institute
1979-	Reviewer, Clinical Chemistry
1982-	Reviewer, Journal of Clinical Immunology
1982-	Reviewer, Journal of Neurosurgery
1983-	Reviewer, Developmental and Comparative Immunology
1984-	Reviewer, Cancer Research
1984-	Associate editor, Journal of Clinical Laboratory Analysis
1986-	Member - Editorial Board, Oncology & Biotechnology News
1986-	Reviewer, Journal of Investigative Dermatology
1987-	External reviewer for grant applications of VA Central Office
1988-	Reviewer, Journal of Biological Response Modifiers
1990-93	Member - Editorial Board, Contemporary Oncology
1994-	Reviewer - Cancer

RESEARCH SUPPORT:

July 1, 1973 to June 30, 1974; Cancer Research Coordinating Committee of the University of California; "Isolation and Purification of Tumor-Associated Antigens from Malignant Melanoma Tumors: Determination of their Reactivity with Homologous Sera"; \$6,480, **R.K. Gupta - Principal Investigator.**

July 1, 1973 to June 30, 1974; California Institute for Cancer Research; "Purification of Specific Antibodies from Sera of Melanoma Patients"; \$6,900; **R.K. Gupta - Principal Investigator.**

July 1, 1974 to June 30, 1975; Cancer Research Coordinating Committee of the University of California; "Isolation and Purification of Tumor-Associated Antigens from Malignant Melanoma Tumors: Determination of their Reactivity with Homologous sera"; \$10,000; **R.K. Gupta - Principal Investigator.**

July 1, 1974 to June 30, 1975; California Institute for Cancer Research, "Isolation and purification of Tumor-Associated Antigens"; \$9,458; **R.K. Gupta - Principal Investigator.**

April 1, 1972 to June 30, 1981; NIH PO1 CA 12582; "Immunology and Immunotherapy of Cancer"; Principal Investigator - Dr. D.L. Morton; **R.K. Gupta - Project Director** on "Purification and Characterization of Tumor Antigens."; Total award for the project component; \$992,000.

April 1, 1981 to March 30, 1984; NIH/NCI RO1 CA 30019; "Purification of Tumor Antigens of Defined Specificities"; \$231,435; R.K. Gupta - Principal Investigator.

July 1, 1981 to June 30, 1982; Cancer Research Coordinating Committee; "Evaluation of Efficacy, Toxicity, and Immune Mechanisms of Extracorporeal Immunoabsorption with Staphylococcus aureus, Cowan I, and Purified Protein A in Producing Tumor Necrosis in Canine Mammary Carcinoma"; \$10,000; R.K. Gupta - Principal Investigator.

July 1, 1981 to June 30, 1986; NIH PO1 CA 12582; "Surgery, Immunology and Immunotherapy of Human Cancer"; Project II - "Characterization of Circulating Immune Complexes and Urinary Antigen of Cancer Patients"; \$354,472; Dr. D.L. Morton - Principal Investigator; R.K. Gupta - Director of Project II.

July 1, 1981 to June 30, 1983; VA Medical Service 821-103; "Prognostic Significance of Circulating Immune Complexes in Human Lung Carcinoma"; \$357,000; D.L. Morton - Principal Investigator; R.K. Gupta - Co-Investigator.

April 1, 1981 to June 30, 1986; NIH P01 CA 29605; "New Approaches to Surgical Oncology"; Project II - "New Approaches to Detection of Subclinical Disease in Stage I and II Melanoma"; \$1,023,285; Dr. D.L. Morton - Principal Investigator; R.K. Gupta - Project Director.

July 1, 1983 to Dec 31, 1988; NIH CA 09010; "Institutional Training Grant and Surgical Oncology"; \$885,000; D.L. Morton Principal Investigator; R.K. Gupta - Co-director.

March 1, 1984 - Feb 28, 1990; NIH R01 CA 30019; "Purification of Tumor Antigens of Defined Specificities"; \$538,115; R.K. Gupta - Principal Investigator.

April 1, 1987 - Dec 31, 1990; NIH P01 CA 12582; "Surgery, Immunology and Immunotherapy of Human Cancer" D.L. Morton Principal Investigator; Project II - "Characterization of Circulating Immune Complexes and Urinary Tumor Antigens of Cancer Patients"; \$262,000; R.K. Gupta - Director of Project II.

April 1, 1987 - Dec 31, 1992; NIH P01 CA 29605; "New Approaches to Surgical Oncology"; D.L. Morton - Principal Investigator, "New Approaches to Detection of Subclinical Disease in Clinical Stage I and II Melanoma"; \$450,000; R.K. Gupta - Director of Project II.

July 1, 1989 to June 30, 1994; NIH T32 CA 09010; "Institutional Training Grant in Surgical Oncology"; \$1,022,533 total award; \$207,804 from 7/1/89 to 6/30/90; D.L. Morton - Principal Investigator; R.K. Gupta - Co-director.

November 8, 1988 - Alex Henig and First Network Savings Bank; "Equipment Purchase" grant; \$15,000, R.K. Gupta Investigator.

March 1 1989 to June 30, 1990; John Wayne Cancer Clinic Auxiliary; "Assessment of Clinical Significance of a 90kD Glycoprotein Tumor-Associated Antigen"; \$250,000; D.L. Morton and R.K. Gupta - Investigators.

July 1, 1990 - June 30, 1991; John Wayne Cancer Clinic Auxiliary; "Assessment of Clinical Significance of a 90kD Glycoprotein Tumor-Associated Antigen"; \$209,000; D.L. Morton and R.K. Gupta - Investigators.

July 1, 1990 to June 30, 1994; State of California, 1RT 77; "Significance of Immune Complexes in Lung Carcinoma"; \$360,445; R. K. Gupta - Principal Investigator.

July 1, 1992 to Sept 29, 1997; NIH PO1 CA12582; Surgery, Immunology and Immunotherapy of Human Cancer; D. L. Morton - PI; R.K. Gupta - Co-investigator; 5% time commitment.

April 1, 1993 to May 31, 1998; NIH PO1 CA29605; New Approaches to Surgical Oncology; D. L. Morton - PI; New Surgical Approaches for the Management of Malignant Melanoma and Other Solid Neoplasms; \$633,144 per year; R.K. Gupta - Co-investigator of Project III.

Oct 1, 1994 to Sept 30, 1998; U.S. Department of Army, Medical Research Acquisition Activity; Grant # DAMD17-94-J-4459; "A New Immunologic Method for Detection of Occult Breast Cancer"; \$800,000; R.K. Gupta - Principal Investigator.

July 1, 1995 to June 30, 1998; NIH T32 CA09689-01A2; "Institutional Training Grant in Surgical Oncology"; \$396,630; P.I. - D.L. Morton, Co-director - R.K. Gupta.

PUBLICATIONS

I. ORIGINAL ARTICLES IN JOURNALS AND MONOGRAMS:

1. Gupta RK, Narayan R and Gollokota KG: Differentiation between heat resistance and octyl alcohol resistance of *Bacillus cereus*. *Biochem Biophys Res Comm* 38:20- 30, 1970.
2. Gupta RK and Pramer D: Amino acid transport by the filamentous fungus *Arthrobotrys conoides*. *J Bacteriol* 103:120-130, 1970.
3. Gupta RK and Pramer D: Metabolism of valine by filamentatous fungus *Arthrobotrys conoides*. *J Bacteriol* 103:131-139, 1970.
4. Stone R and Gupta RK: Aerobic and anaerobic landfill stabilization process. *J Sanit Eng Div, Amer Soc Civil Eng* 96:1399-1414, 1970.
5. Gupta RK and Narayan R: Octyl alcohol resistance of *Bacillus cereus*. Factors influencing dipicolinic acid synthesis and sporulation in bacilli. IN: U.P. Agri Univ Res Bull. Gollakota KG (ed.) 2:257-263, 1970.
6. Gupta RK and Howard DH: Comparative physiological studies of the yeast and mycelial forms of *Histoplasma capsulatum*: Uptake and incorporation of L-leucine. *J Bacteriol* 105:690-700, 1971.
7. Howard DH, Otto V and Gupta RK: Lymphocyte mediated cellular immunity in histoplasmosis. *J Infec Immunity* 4:605-610, 1971.
8. Howard DH and Gupta RK: Lysis of zoopathogenic fungi by streptomycetes. *Can J Microbiol* 17:521-523, 1971.
9. Irie K, Gupta RK and Morton DL: Preparation of single cell suspension from surgical specimens of human tumors. *Jap Assoc Immunol* 4:903-906, 1974.
10. Gupta RK, Irie-K and Morton DL: Ultra-micro complement fixation technique. *Jap Assoc Immunol* 4:939-950, 1974.
11. Gupta RK and Morton DL: Suggestive evidence for in vivo binding of specific anti-tumor antibodies of human melanomas. *Cancer Res* 35:58-62, 1975.

12. **Gupta RK** and Morton DL: Presence of human tumor-associated antigens in urine of cancer patients. *Surg Forum* 26:158-160, 1975.
13. Morton DL, Golub SH, Sulit HL, **Gupta RK**, Eilber FR, Holmes EC and Sparks FC: Immunologic and clinical responses to active immunotherapy of a malignant melanoma. IN: *Fundamental Aspects of Neoplasia*. Gotteleib, Plescia and Bishop (eds.) Springer-Verlag Inc., New York, pp. 181-201, 1975.
14. deKernion JB, Golub SH, **Gupta RK**, Silverstein MJ and Morton DL: Successful transurethral intralesional BCG therapy of a bladder melanoma. *Cancer* 36:1662- 1667, 1975.
15. Roth JA, Silverstein MJ, **Gupta RK** and Morton DL: Restoration of Immunocompetence by lymphocyte transfusion. *J Surg Oncol* 7:63-66, 1975.
16. Sulit HL, Golub SH, Irie RF, **Gupta RK**, Grooms GA and Morton DL: Fetal calf serum-grown human tumor cells: Influences on the tests for lymphocytotoxicity, serum blocking and arming effect. *Int J Cancer* 17:461-468, 1976.
17. Grimm EA, Silver HKB, Roth JA, Chee DO, **Gupta RK** and Morton DL: Detection of tumor-associated antigen in human melanoma cell line supernatants. *Int J Cancer* 17:559-564, 1976.
18. **Gupta RK**, Irie RF, Morton DL: Antigens on human tumor cells assayed by complement fixation with allogeneic sera. *Cancer Res* 38:2573-2580, 1978.
19. **Gupta RK**, Golub SH, Rangel DM and Morton DL: Relationship between anticomplementary activity and inhibition of PHA-induced lymphocyte blastogenesis by melanoma sera. *Proc ASM 2nd Annual Meeting of Diagnostic Immunology*, 1978.
20. Tang SL, Howard DH and **Gupta RK**: Uptake of metabolites by germinating blastospores of *Histoplasma capsulatum*. *Sabouraudia* 16:271-278, 1978.
21. **Gupta RK**, Golub SH, Rangel DM and Morton DL: Inhibition of mitogen induced lymphocyte proliferation correlated to anticomplementary activity in sera from melanoma patients. *Cancer Immunol Immunother* 5:221-228, 1979.
22. **Gupta RK**, Golub SH and Morton DL: Correlation between tumor burden and anti-complementary activity in sera from cancer patients. *Cancer Immunol Immunother* 6:63-71, 1979.
23. **Gupta RK** and Morton DL: Detection of cancer associated antigen(s) in urine of sarcoma patients. *J Surg Oncol* 11:65-74, 1979.
24. deKernion JB, Ramming KP and **Gupta RK**: The detection and clinical significance of antibodies to tumor associated antigens in patients with renal cell carcinoma. *J Urology* 122:300-305, 1979.
25. **Gupta RK**, Irie RF, Chee DO, Kern DH and Morton DL: Demonstration of two distinct antigens in spent tissue culture medium of a human malignant melanoma cell line. *J Natl Cancer Inst* 63:347-356, 1979.
26. **Gupta RK**, Silver HKB, Reisfeld RA and Morton DL: Isolation and immunochemical characterization of antibodies from cancer patients sera reactive against human melanoma cell membranes by affinity chromatography. *Cancer Res* 39:1683-1695, 1979.
27. **Gupta RK** and Morton DL: Double-antibody method and the Protein-A bearing *Staphylococcus aureus* cells method compared for separating bound and free antigen in radioimmunoassay. *Clin Chem* 25:752-756, 1979.

28. **Gupta RK**, Theofilopolous AN, Dixon FJ and Morton DL: Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. *Cancer Immunol Immunother* 6:211-221, 1979.
29. Roth JA, Chee DO, **Gupta RK** and Morton DL: Lymphocyte stimulation to tumor associated antigen. II. Comparison of extracts from fresh human tumors with tissue culture cell lines. *Cancer Immunol Immunother* 7:25-29, 1979.
30. Huth JF, **Gupta RK** and Morton DL: Sequential analysis of urinary antigen(s) in patients with sarcoma. *Surg Forum* 30:150-152, 1979.
31. **Gupta RK**, Silver HKB and Morton DL: Production and Characterization of xenogeneic antisera to tumor associated antigens. *J Surg Oncol* 13:75-89, 1980.
32. Chee DO, **Gupta RK** and Morton DL: Presence of a carcinoma associated antigen in the spent chemically defined medium of a human colon carcinoma cell line. *J Surg Oncol* 13:45-51, 1980.
33. **Gupta RK** and Morton DL: Radioimmunoassay for the analysis of tumor associated antigens with allogeneic antibody. IN: *Serologic Analysis of Human Tumor Antigens*. S.A. Rosenberg (ed.) Academic Press, pp. 645-650, 1980.
34. Rote NS, **Gupta RK** and Morton DL: Tumor associated antigen detected by autologous sera in urine of patients with solid neoplasms. *J Surg Res* 29:18-22, 1980.
35. Chee DO and **Gupta RK**: Chemical carcinogenesis and tumor immunology. IN: *Genetic Differences and Chemical Carcinogenesis*. CRC Monogram, pp. 151-184, 1980.
36. Rote NS, **Gupta RK** and Morton DL: Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors. *Int J Cancer* 26:203-210, 1980.
37. Higuchi M, **Gupta RK**, Irie RF and Morton DL: Natural humoral immunity in patients with malignant disease. *J Clin Lab Immunol* 4:141-143, 1980.
38. Renk CM, **Gupta RK** and Morton DL: Immunosuppressive factors from human breast carcinoma cell lines that affect inhibition of lymphocyte proliferation. *Cancer Immunol Immunother* 9:55-62, 1980.
39. **Gupta RK**: Antigenic complexity in human malignant tumors detected by allogeneic antibody. IN: *Serologic Analysis of Human Tumor Antigens*. S.A. Rosenberg (ed.) Academic Press, pp. 339-380, 1980.
40. **Gupta RK** and Morton DL: Detection of tumor antigens by complement fixation using allogeneic antibody. IN: *Serologic Analysis of Human Tumor Antigens*. S.A. Rosenberg (ed.) Academic Press, pp. 611-619, 1980.
41. **Gupta RK** and Morton DL: Possible clinical significance of circulating immune complexes in melanoma patients. IN: *Fundamental Mechanisms in Human Cancer Immunology*. p. 305-320, 1981.
42. **Gupta RK** and Morton DL: Clinical significance and nature of circulating immune complexes in melanoma patients. IN: *Contemporary Topics in Immunobiology*. F.A. Salinas (ed.) Plenum Press, New York, 15:1-53, 1984.
43. Renk CM, **Gupta RK** and Morton DL: Inhibition of normal allogeneic lymphocyte mitogenesis by a factor from human tumor cells in culture. *Cancer Immunol Immunother* 11:7-16, 1981.

44. Fox JN, Sheikh KM, Gupta RK, Rea TH, Morton DL and Levan NE: Melanoma associated antigens in benign melanocytic disorders. *Dermatol* 20:368-373, 1981.
45. Huth JF, Gupta RK and Morton DL: Development of an enzyme immunoassay to detect and quantitate tumor-associated antigens in the urine of sarcoma patients. *Cancer* 47:2856-2861, 1981.
46. Huth JF, Gupta RK and Morton DL: Purification of antigen(s) from urine of a sarcoma patient by affinity chromatography. *J Surg Oncol* 18:237-247, 1981.
47. Huth JF, Gupta RK and Morton DL: Assessment of the in vivo effectiveness of tumoricidal chemotherapy and radiation therapy by serial analysis of tumor-associated urinary antigen titers in sarcoma patients. *Cancer Treat Rep* 65:1037-1042, 1981.
48. Huth JF, Gupta RK and Morton DL: The relationship of tumor-associated urinary antigens to disease recurrence in melanoma patients. *Surg Forum*, 32:417-419, 1981.
49. Huth JF, Gupta RK and Morton DL: Relationship between circulating immune complexes and urinary antigens in human malignant malignancy. *Cancer* 48:1150-1157, 1982.
50. Roth JA, Grimm EA, Gupta RK and Ames RS: Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. *J Immunol* 128:1955-1962, 1982.
51. Bentwich Z, Fahey J, Gupta RK, Golub S, Chia D and Barnett E: Comparison of assays for circulating immune complexes in human diseases. IN: *Progress in Rheumatology*. I. Machtey (ed.) John Wright-PSG Inc, Boston, pp. 23-31, 1982.
52. Gupta RK and Morton DL: Clinical significance of tumor-associated antigens and antitumor antibodies in human malignant melanoma. IN: *Melanoma Antigens and Antibodies*. R.A. Reisfeld (ed.) Plenum, New York, pp. 139-172, 1982.
53. Gupta RK and Howard DH: Metabolite transport. IN: *Fungi Pathogenic for Humans and Animals*, Vol. 1. D.H. Howard (ed.) Marcel Dekker Inc. New York, pp. 547- 591, 1982.
54. Finck S, Gupta RK and Morton DL: Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma. *J Surg Oncol* 21:84-89, 1982.
55. Renk CM, Gupta RK, Irie RF, Morton DL. Comparison of the techniques used for monitoring humoral immunity in cancer patients. *J Surg Oncol* 19:155-161, 1982.
56. Gupta RK, Huth JF, Golub SH: Application of cultured human myeloid cells (K562) for detection of immune complexes in human sera. *Immunol Commun* 11:401-419, 1982.
57. Ahn SS, Gupta RK, Morton DL: Predictive value of circulating immune complexes for tumor recurrence in stage I malignant melanoma. *Surg Forum* 33:415-417, 1982.
58. Leitch AM, Gupta RK, Morton DL: Immunoabsorption with protein A-bearing *Staphylococcus aureus* for treatment of metastatic cancer. *Surg Forum* 33:412-414, 1982.
59. Huth JF, Gupta RK, Eilber FR, Morton DL: Predictive value of urinary antigen titers for disease recurrence in sarcoma patients. *Surg Forum* 33:417-419, 1982.

60. Gupta RK and Morton DL: Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. *J Natl Cancer Inst* 70:993-1004, 1983.
61. Gupta RK, Leitch AM and Morton DL: Detection of tumor-associated antigen in eluates from protein A columns used for ex vivo immunoadsorption of plasma from melanoma patients by radioimmunoassay. *Clin Exp Immunol* 53:589-599, 1983.
62. Chee DO, Gupta RK and Morton DL: Humoral immune responses of melanoma patients to two different tumor-associated antigens. *J Surg Oncol* 23:288-235, 1983.
63. Gupta RK, Leitch AM and Morton DL: Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. *Cancer Immunol Immunother* 6:40-47, 1983.
64. Gupta RK, Huth JF, Korn EL and Morton DL: Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients. *Diagnostic Immunol* 1:303-309, 1983.
65. Gupta RK, Morton DL: Tumor Antigens. IN: *Immunobiology of Cancer, Transplantation and Pregnancy*, PK Ray (ed), Pergamon Press, New York, pp. 113-147, 1983.
66. Gupta RK and Morton DL: Studies of a melanoma tumor-associated antigen detected in spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay. *J Natl Cancer Inst* 72:67-74, 1984.
67. Gupta RK and Morton DL: Studies of a melanoma tumor-associated antigen detected in spent culture medium of a human melanoma cell line by allogeneic antibody. II. Immunological characterization. *J Natl Cancer Inst* 72:75-82, 1984.
68. Gupta RK and Morton DL: Studies of a melanoma tumor-associated antigen detected in spent culture medium of a human melanoma cell line by allogeneic antibody. III. Physicochemical properties. *J Natl Cancer Inst* 72:83-92, 1984.
69. Huth JF, Gupta RK, Eilber FR, Morton DL: A prospective postoperative evaluation of urinary tumor associated antigen in sarcoma patients: Correlation with disease recurrence. *Cancer* 53:1307-1310, 1984.
70. Morton DL, Gupta RK, Huth JF: *New horizons in surgical oncology: Malignant melanoma. Basic Mechanisms and Clinical Treatment of Tumor Metastasis*. Academic Press, New York, pp 567-571, 1985.
71. Cheng WC, Gupta RK, Morton DL: Characterization of antigenic components of immune complexes isolated from a melanoma patient. *Immunol Invest* 14:367-378, 1985.
72. Wong JH, Gupta RK, Morton DL: Serial determinations of tumor-associated antigen and antibody complexes in stage I melanoma patients. *Arch Surg* 121:1342-1345, 1986.
73. Hoon DBS, Wen D-R, Stene M, Gupta RK, Cochran AJ: Leukocyte migration inhibition by interleukin-2. *Clin Exp Immunol*. 66:566-573, 1986.
74. Hetzitheofilou C, Campbell MA, Gupta RK, Kern DH, Morton DL: A radioimmunometric assay for detection and characterization of lung cancer associated antibodies in sera of lung cancer patients. *J Surg Res*. 42:85-91, 1987.
75. Chee DO, Gupta RK, Gosselin EJ, Witman GB: Detection of tumor-associated antigen in cancer patients' sera by F-11 monoclonal antibody. *Protids of Protein Chem*, 1987.

76. Gupta RK: Circulating immune complexes in malignant melanoma. *Disease Markers* 6:81-96, 1988.
77. Wong JH, Gupta RK, Morton DL: Recovery of a cell surface fetal antigen and antibody in Stage I melanoma patients. *Cancer Immunol Immunother* 27:142-146, 1988.
78. Wong JH, Gupta RK, Morton DL: Demonstration of a well characterized tumor associated antigen on melanoma cell surface. *J Surg Oncol* 38:147-150, 1988.
79. Gupta RK: Detection and characterization of melanoma tumor associated antigens. *Medicina* 48:695-708, 1988.
80. Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. *Cancer Immunol Immunother* 29:247-254, 1989.
81. Euhus DM, Gupta RK, Morton DL: Detection of a tumor associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay. *J Clin Lab Anal* 3:184-190, 1989.
82. Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, Hoon DBS, Irie RF: Active specific immunotherapy in malignant melanoma. *Sem Surg Oncol* 5:420-425, 1989.
83. Wong JH, Xu SH, Saxton RE, Gupta RK, Morton DL: Detection and isolation of antigen-specific immune complexes from sera of melanoma patients. *Int J Cancer* 45:445-449, 1990.
84. Wong JH, Xu SH, Gupta RK, Morton DL: Tumor associated antigen immune complexes. *Arch Surg* 125:187-191, 1990.
85. Euhus DM, Gupta RK, Morton DL: Characterization of a 90-100kDa tumor associated antigen in sera of melanoma patients. *Int J Cancer* 45:1065-1070, 1990.
86. Wong JH, Xu SH, Saxton RE, Gupta RK, Morton DL: Immunochemical characterization of a tumor-associated antigen defined by a monoclonal antibody. *J Surg Res* 48:539-546, 1990.
87. Euhus DM, Gupta RK, Morton DL: Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor associated antigen. *Cancer Immunol Immunother* 32:214-220, 1990.
88. Lindemann RA, Singh KP, Shau H, Gupta RK. The effects of staphylococcal protein A on human lymphokine-activated killer cell induction. *Cancer Immunol Immunother* 33:97-102, 1991.
89. Singh KP, Shau H, Gupta RK, Kopald K, Ray PK. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes. *Immunopharmacol Immunotoxicol* 14:73-103, 1992.
90. Hunt KK, Shibata M, Gupta RK, Morton DL. Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen. *Cancer Immunol Immunother* 34:377-82, 1992.
91. Morton DL, Foshag LL, Hoon DBS, Nizze JA, Wanek L, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. *Ann Surg* 216:463-482, 1992.
92. Morton DL, Hoon DBS, Gupta RK, Nizze A, Foshag LJ, Irie RF: Active specific immunotherapy of malignant melanoma. In *Cutaneous Melanoma*, Second Edition, Balch CM, Houghton AN, Milton GW, Sober AJ and Seng-jaw, eds. JB Lippincott Co., Philadelphia, pp 544-546, 1992.

93. Gupta RK, Morton DL: Monoclonal antibody based ELISA to detect glycoprotein tumor-associated antigen specific immune complexes in cancer patients. *J Clin Lab Analysis* 6:329-336, 1992.
94. Shau H, Gupta RK, Golub SH: Induction of a natural killer enhancing factor (NKEF) from human erythroid cells. *Cell Immunol* 147:1-11, 1993.
95. Morton DL, Hoon DBS, Nizze A, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. In Bystryk J-C, Ferrone S, Livingston P (eds.): *Specific Immunotherapy of Cancer with Vaccine*. Ann NY Acad Sci 690:120-135, 1993.
96. Morton DL, Nizze JA, Hoon DBS, Foshag LJ, Famatiga E., Gupta RK, Ramming KP: Improved survival of metastatic melanoma patients receiving active specific immunotherapy with a polyvalent whole-cell vaccine. In *Adjuvant Therapy for Cancer VII*, Slamon SE (ed.) JB Lippincott Co. Philadelphia, pp398-404, 1993.
97. Singh KP, Gupta RK, Shau H, Ray PK: Effect of ASTA-Z (immaphosphamide) on human lymphokine activated killer cell induction. *Immunopharmacol Immunotoxicol* 15:525-538, 1993.
98. Gupta RK, Morton DL: Prognostic value of a 90kD subunit containing glycoprotein tumor-associated antigen specific immune complexes in lung cancer patients. *Disease Markers* 12:51-61, 1994.
99. Gupta RK, Morton DL: Glycoprotein tumor-associated antigen specific immune complexes in sera of breast cancer patients. In *XVI International Cancer Congress*, Monduzzi Editore, Bologna, Italy, pp 1333-1337, 1994.
100. Gupta RK, Morton DL: Detection and comparison of a 90kD glycoprotein tumor associated antigen specific immune complexes with CEA and CA15-3 in breast cancer. *Int J Oncol (In press)*, 1995.
101. Gupta RK, Morton DL: Association between a 90kD glycoprotein tumor-associated antigen specific immune complexes and breast cancer. (*Submitted*).

II. INVITED ARTICLES:

1. Gupta RK, Silver HKB, Reisfeld RA, Morton DL: Isolation and characterization of antitumor antibodies by affinity chromatography. International Medical News Group, 1978.
2. Gupta RK, Morton DL: Urinary excretion of tumor antigens in sarcoma patients. *Urology Observer*, 1979.
3. Gupta RK, Silver HKB, Reisfeld RA, Morton DL: Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography. *Year Book of Cancer*, pp. 283-287, 1980.
4. Finck SJ, Gupta RK, Giuliano AE, Morton DL: Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma. *Current Surgery* 40:305-306, 1983.

III. ABSTRACTS:

1. Gupta RK and Pramer D: Amino acid transport in filamentous fungi. *Bacteriol Proc* 68:124, 1968.
2. Gupta RK and Pramer D: Transport and metabolism of valine in *Arthrobotrys conoides*. Theobald Smith Society, New Jersey, 1968.
3. Howard DH, Otto V and Gupta RK: Cellular immunity to histoplasmosis. *Bacteriol Proc* 71:117, 1971.

4. Howard DH and Gupta RK: The intercellular fate of *Histoplasma capsulatum*. *Bacteriol Proc* 72:133, 1972.
5. Gupta RK: Elution of antibodies from human malignant melanomas. *Proc Amer Assoc Cancer Res* 15:87, 1974.
6. Gupta RK: Common cancer-associated antigen(s) in human neoplasms. *Proc Amer Soc Clin Oncol* 11:262, 1975.
7. Gupta RK, Yee R, Irie RF and Morton DL: Immunologic differentiation between human tumor-associated antigen(s) and heterologous antigens. *Proc Amer Assoc Cancer Res* 16:146, 1975.
8. Gupta RK and Morton DL: Tumor associated antigens in urine of cancer patients. *Proc Amer Assoc Cancer Res* 17:92, 1976.
9. Naness J, Sheikh K, Gupta RK, Rea T, Frion G, Morton DL and Levan N: Antibodies to melanoma associated antigens in benign melanocytic disorders. *Proc Clin Res*, p. 266A, 1976.
10. Gupta RK and Morton DL: Distribution of antibodies to common tumor associated antigens in cancer and non-cancer sera. *Proc Amer Assoc Cancer Res* 18:184, 1977.
11. Rangel DM, Gupta RK, Golub SH and Morton DL: Demonstration of tumor associated antigenic activity in immunosuppressive melanoma sera. *Proc Amer Assoc Cancer Res* 18:194, 1977.
12. Ramming KP, Gupta RK and deKernion JB: Detection of antibodies to tumor associated antigens in patients with hypernephroma. *Proc Amer Soc Clin Oncol* 18:313, 1977.
13. Gupta RK, Silver HKB, Reisfeld RA and Morton DL: Isolation and characterization of anti-tumor antibodies from cancer patients sera by affinity chromatography. *Proc Amer Soc Clin Oncol* 19:360, 1978.
14. Gupta RK, Silver HKB, Morton DL and Penderleith IG: Reactivity of human tumor extracts to xenogeneic antisera raised against human melanoma extract. *Proc Amer Soc Clin Oncol* 19:360, 1978.
15. Gupta RK and Morton DL: Tumor related immune complexes in sera from melanoma patients. *Fed Proc* 37:595, 1978.
16. Kern DH, Gupta RK, Hencock WK and Holmes EC: An inhibition of binding assay for the detection of soluble melanoma associated antigen. *Proc Amer Assoc Cancer Res* 19:134, 1978.
17. Rote NS, Gupta RK and Morton DL: Detection of tumor-associated antigen in the urine of sarcoma patients. *Proc Amer Assoc Cancer Res* 19:134, 1978.
18. Chee DO, Gupta RK and Morton DL: Carcinoma associated antigen(s) in spent medium of HT-29 colon carcinoma grown in serum free medium. *Proc Amer Assoc Cancer Res* 19:135, 1978.
19. Gupta RK and Morton DL: Protein A bearing *Staphylococcus aureus* (Cowan I) as immunosorbant in a radioimmunoassay. *Clinical Radio Assay Society, Fourth Annual Meeting*, 1978.
20. Gupta RK, Irie, Chee DO, Kern DH and Morton DL: Antigens in spent serum-free medium of a human melanoma cell line. *Bacteriol Proc* 78:54, 1978.
21. Chee DO, Gupta RK and Morton DL: Humoral response to BCG and allogeneic melanoma cells in stage II postoperative melanoma patients. *Tissue Culture Assoc*, p. 370, 1978.

22. Gupta RK, Morton DL and Golub SH: Detection of immune complex-like material in human sera by binding to cultured myeloid (K562) cells. Fed Proc 38:1358, 1979.
23. Ramming KP, Gupta RK, deKernion JB: Induction of antibody to human renal cell cancer in vivo by injections of xenogeneic immune RNA. Proc Amer Assoc Cancer Res 20:215, 1979.
24. Gupta RK and Morton DL: Quantitation of allogeneic antibody to tumor-associated antigen by radioimmunoassay, Proc Amer Assoc Cancer Res 20:216, 1979.
25. Huth JF, Gupta RK and Morton DL: Urinary antigen titers in sarcoma patients. Proc Amer Assoc Cancer Res 20:217, 1979.
26. Gupta RK, Golub SH, Hammond WG and Morton DL: Correlation between incidence of serum anticomplementary activity and tumor burden. Proc Amer Soc Clin Oncol 20:331, 1979.
27. Gupta RK and Morton DL: Specificity by radioimmunoassay of tumor-associated antigen isolated from spent culture medium of a melanoma cell line. Fed Proc 39:1144, 1980.
28. Huth JF, Gupta RK and Morton DL: Competitive inhibition enzyme immunoassay for detection of melanoma-associated urinary antigen. Proc Amer Soc Clin Oncol 21:370, 1980.
29. Goodnight JE Jr, Irie RF, Saxton RE, Gupta RK, Ramming KP and Morton DL: Humoral immune response to bone and soft tissue sarcomas. Proc Amer Soc Clin Oncol 21:370, 1980.
30. Gupta RK, Huth JF, Golub SH and Morton DL: Quantitation of immune complexes in cancer sera. Proc Amer Assoc Cancer Res 21:222, 1980.
31. Roth JA, Grimm EA, Gupta RK, Morton DL and Eilber FR: Purification of an immunoregulatory factor in extracts of lung carcinoma. Proc Amer Assoc Cancer Res 21:222, 1980.
32. Hatzitheofilou C, Kern DH, Gupta RK, Morton DL and Storm FK: Definition of antigens associated with human lung carcinoma. Proc Amer Assoc Cancer Res 21:223, 1980.
33. Roth JA, Grimm EA, Gupta RK and Morton DL: Characterization and purification of an immunosuppressive factor in extracts of lung carcinoma. Fourth International Congress of Immunology, Paris, 1980.
34. Roth JA, Grimm EA, Gupta RK, Sugarbaker PH and Ames R: Suppression of lymphocyte proliferative and cytotoxic responses by human tumor-associated immunoregulatory factors. 14th International Leukocyte Culture Conference, Heidelberg, 1981.
35. Gupta RK, Cheng LY, Leitch AM and Morton DL: Characterization of tumor-associated antigen isolated from spent culture medium of a human melanoma cell line. Fed Proc 40:981, 1981.
36. Roth JA, Grimm EA, Gupta RK, Ames R, Trehan E: Presence of immunoregulatory factors in extracts from several histologically distinct human malignancies. Fed Proc 40:1089, 1980.
37. Finck S, Gupta RK and Morton DL: Serum LDH in stage II melanoma patients. Proc Amer Soc Clin Oncol 22:344, 1981.
38. Cheng LY, Gupta RK, Huth JF and Morton DL: Characterization of urinary antigen detected in melanoma patients by autologous and allogeneic antibody. Proc Amer Assoc Cancer Res 22:292, 1981.

39. Leitch AM, Gupta RK, Eilber FR and Morton DL: Correlation of the presence of melanoma-associated antigen in urine and serum by competitive enzyme immunoassay. *Proc Amer Assoc Cancer Res* 22:296, 1981.
40. Finck S, Gupta RK, Storm FK and Morton DL: Tumor-associated antigens in the urine of patients with colon carcinoma: A preliminary study. *Proc Amer Assoc Cancer Res* 22:299, 1981.
41. Gupta RK, Huth JF and Morton DL: Characterization of antigen component of immune complexes isolated from sera of melanoma patients. *Proc Amer Assoc Cancer Res* 22:293, 1981.
42. Gupta RK and Morton DL: Detection and quantitation of oncofetal antigen and its chemical characterization. *Proc Oncodevel Biol Med* 1:47, 1981.
43. Finck S, Giuliano AE, Gupta RK and Morton DL: Tumor-associated antigens in the urine of carcinoma patients. *Proc Amer Assoc Cancer Res* 23:272, 1982.
44. Leitch AM, Gupta RK and Morton DL: Isolation of tumor-associated antigen (TAA) from serum of melanoma patients. *Proc Amer Soc Clin Oncol* 1:42, 1982.
45. Gupta RK and Morton DL: Use of ¹²⁵I-labelled tumor-associated antigen to characterize immune complexes circulating in melanoma patients. 13th International Cancer Congress, pp. 309, 1982.
46. Gupta RK and Morton DL: Nature of circulating immune complexes in melanoma patients. *Fed Proc* 41:323, 1982.
47. Gupta RK, Leitch AM, Morton DL: Characterization immune complexes isolated by staphylococcal protein A from melanoma patients. *Fed Proc* 42:403, 1983.
48. Gupta RK, Leitch AM, Morton DL: Tumor-associated antigen in eluates of protein A columns used for ex vivo immunoadsorption of melanoma patients. *Proc Amer Assoc Cancer Res* 24:201, 1983.
49. Gupta RK, Huth JF, Korn EL, Morton DL: Urinary antigen analysis by enzyme-linked immunosorbent assay: Prognostic significance for melanoma patients. *Proc Amer Soc Clin Oncol* 2:49, 1983.
50. Gupta RK, Morton DL: Physicochemical characterization of a melanoma tumor-associated antigen. International Immunology Congress, Kyoto, Japan, 1983.
51. Cheng WC, Gupta RK, Morton DL: Isolation of tumor-associated antigens from circulating immune complexes of melanoma serum. *Proc Amer Assoc Cancer Res* 25:242, 1984.
52. Gupta RK, Huth JF, Morton DL: Immunologic similarity between tumor-associated antigens detected in urine of melanoma patients and those expressed by melanoma cells. *Proc Amer Soc Clin Oncol* 3:9, 1984.
53. Gupta RK, Morton DL: Dynamics of tumor-associated antigen, antibody, and immune complexes circulating in melanoma patients. *Proc Amer Assoc Cancer Res* 26:284, 1985.
54. Gupta RK, Morton DL: Detection of tumor-associated antigen, antibody and immune complexes in sera from melanoma patients. *Proc Amer Soc Clin Oncol* 4:16, 1985.
55. Neslund GG, Gupta RK: Partial purification and characterization of melanoma-associated urinary antigen. *Fed Proc* 4:795, 1985.

56. Gupta RK, Morton DL: Immunochemical characterization of tumor-associated antigens excreted into urine of melanoma patients. *Proc Am Assoc Cancer Res* 27:354, 1986.
57. Gupta RK, Euhus DM, Morton DL: Detection of tumor-associated antigen in urine of melanoma patients by allogeneic antibody. *Fed Proc.* 48:1059, 1987.
58. Gupta RK, Morton DL: In vitro production of antibodies to a melanoma tumor-associated antigen by Epstein Barr virus transformed human lymphoblastoid cells. *Proc Am Assoc Cancer Res.* 28:349, 1987.
59. Wong JH, Gupta RK, Storm FK, Morton DL: Demonstration of a cell surface fetal antigen in circulating immune complexes of melanoma patients. *Proc Am Assoc Cancer Res.* 28:357, 1987.
60. Morton DL, Hoon DBS, Niku DS, Gupta RK: Suppressor T-cell activity against human melanoma tumor-associated antigen (M-TAA) antibody production. *Proc Am Assoc Cancer Res.* 28:374, 1987.
61. Gupta RK, Wong JH, Morton DL: Increase in antibody level to a tumor-associated antigen in melanoma patients undergoing immunotherapy with a tumor cell vaccine. *Proc Am Soc Clin Oncol.* 6:249, 1987.
62. Wong JH, Gupta RK, Eilber FR, Morton DL: Demonstration of the presence of a melanoma tumor-associated antigen on the cell surface. *Proc Am Soc Clin Oncol.* 6:242, 1987.
63. Gupta RK, Wong JH, Morton DL: Clinical relevance of a tumor-associated antigen in malignant melanoma. *J Steroid Chem.* 28:1255, 1987.
64. Morton DL, Nizze JA, Gupta RK, Famatiga E, Hoon DBS, Irie RF: Active specific immunotherapy of malignant melanoma. IN: *Current Status of Cancer Control and Immunology*, Kim JP, Kim BS, Park J-G (eds), Seoul, pp 152-161, 1987.
65. Morton DL, Hoon DBS, Gupta RK, Nizze JA, Irie RF: Humoral immune response in melanoma patients receiving active specific immunotherapy of melanoma tumor cell vaccine (MCV) alone or combined with low dose cyclophosphamide (CYP). *J Leuk Biol* 40:357, 1987.
66. Euhus DM, Gupta RK, Wong JH, Ramming KP, Morton DL: Effect of melanoma cell vaccine on level of antibody to a tumor associated antigen in melanoma patients, *Proc Amer Assoc Cancer Res* 28:349, 1987.
67. Gupta RK, Wong JH, Euhus DM, Morton DL: Detection of tumor antigen specific immune complexes in sera of melanoma patients and its relationship with disease recurrence. *FASEB* 2:1470, 1988.
68. Morton DL, Nizze JA, Hoon DBS, Famatiga E, Gupta RK Irie RF: A trial of immunomodulation in patients receiving active specific immunotherapy with melanoma cell vaccine (MCV). *International Symposium on Molecular Probes, Technology and Medical Applications*, 1988.
69. Euhus DM, Langsford C, Gupta RK, Wong JH, Morton DL: Measurement of a glycoprotein tumor associated antigen (TAA) using antibodies of different isotypes from a melanoma patient. *Proc FASEB J* 2:A1836, 1988.
70. Euhus DM, Gupta RK, Wong JH, Morton DL: Demonstration and isolation of a glycoprotein tumor associated antigen from sera of melanoma patients. *Proc Am Soc Clin Oncol* 7:44, 1988.
71. Euhus DM, Gupta RK, Wong JH, Ramming KP, Morton DL: Murine monoclonal antibody to a glycoprotein tumor associated antigen in sera and urine of melanoma patients. *Proc Am Assoc Cancer Res* 29:393, 1988.

72. Gupta RK, Wong JH, Euhus DM, Morton DL: Immunoprognostic significance of tumor associated antigen specific immune complexes in melanoma patients. *Proc Am Assoc Cancer Res*, 29:390, 1988.
73. Wong JH, Gupta RK, Huth JH, Euhus DM, Morton DL: Augmentation of anti-fetal antigen antibody levels in melanoma patients undergoing active specific immunotherapy with a tumor cell vaccine. *Proc Am Soc Clin Oncol* 7:248, 1988.
74. Wong JH, Gupta RK, Euhus DM, Morton DL: 69.5 kD glycoprotein fetal antigen tumor marker in melanoma. *Proc Am Soc Clin Oncol* 7:252, 1988.
75. Gupta RK, Wong JH, Morton DL: Correlation of humor immune response to a melanoma tumor associated antigen with survival of melanoma patients receiving active specific immunotherapy. *Proc Am Assoc Cancer Res* 30:344, 1989.
76. Wong JH, Xu SH, Gupta RK, Morton DL: IgG monoclonal antibody to detect and isolate antigen specific immune complexes from sera of melanoma patients. *Proc Am Assoc Cancer Res* 30:355, 1989.
77. Kopald KH, Shibata M, Gupta RK, Guiliano AE, Morton DL: Complement dependent cytotoxicity against tumor cell lines by a purified baboon IgM antibody to a tumor associated antigen. *Proc Amer Assoc Cancer Res* 30:346, 1989.
78. Bauer R, Kopald K, Gupta RK, Euhus D, Morton D: Detection of tumor antigen containing immune complexes in sera of cancer patients. *Proc Amer Assoc Cancer Res* 30:358, 1989.
79. Kopald K, Bauer R, Gupta RK, Euhus D, Morton D: Immunoprognostic significance of a tumor associated antigen excreted into the urine of melanoma patients. *Proc Amer Soc Clin Oncol* 8:290, 1989.
80. Morton DL, Hoon DBS, Gupta RK, Nizze AJ, Famatiga E, Foshag LJ, Furutani S, Irie RF: Treatment of malignant melanoma by active specific immunotherapy in combination with biological response modifiers. IN: *New Horizons of Tumor Immunotherapy*. Torisu M, Yshida T (eds), Elsevier Science Publishers B.V., pp 665-683, 1989.
81. Morton DL, Hoon DBS, Foshag LJ, Nizze A, Famatiga E, Gupta RK, Irie RF: Clinical results of a trial of active specific immunotherapy with melanoma cell vaccine and modulation in metastatic melanoma. Venice, Italy, 1989.
82. Morton DL, Nizze A, Famatiga E, Hoon DBS, Gupta RK, Irie RF: Clinical results of a trial of active specific immunotherapy and immunomodulation in metastatic melanoma. *Proc Amer Assoc Cancer Res* 30:383, 1989.
83. Shibata, M, Gupta RK, Morton DL: Assessment of histamine H₂ receptors on human peripheral blood lymphocytes in a competitive radioligand binding assay. *Proc Amer Assoc Cancer Res* 30:386, 1989.
84. Wong JH, Xu SH, Gupta RK, Morton DL: Correlation of a tumor associated antigen specific immune complexes in sera of melanoma patients with recurrence disease. *Proc Amer Assoc Cancer Res* 9:278, 1990.
85. Bauer R, Gupta RK, Kopald K, Morton D: Improved immunoassay to detect antigen specific immune complexes in sera of cancer patients. *Proc Amer Assoc Cancer Res* 31:263, 1990.
86. Kopald K, Gupta RK, Bauer R, Morton D: Diurnal variation in the excretion of tumor associated antigen into the urine of cancer patients. *Proc Amer Assoc Cancer Res* 31:261, 1990.
87. Morton DL, Nizze A, Foshag LJ, Hoon DS, Famatiga E, Gupta RK, Irie, R: Long-term survival in metastatic melanoma after active specific immunotherapy with melanoma cell vaccine and immunomodulation. *Proc Amer Assoc Cancer Res* 31:281, 1990.

88. Gutierrez D, Hoon DS, Foshag LJ, Gupta RK, Morton DL: Enhancement of melanoma-associated antigen antibodies by melanoma patients' lymphocytes in vitro by interleukins 2, 4, 6 or 7. *Proc Amer Assoc Cancer Res* 31:241, 1990.
89. Morton DL, Hoon D, Nizze A, Foshag L, Gupta R, Irie RF: Active specific immunotherapy with melanoma cell vaccine and immunomodulation in patients with metastatic melanoma. *Proc Amer Soc Clin Oncol* 10:295, 1991.
90. Prasad R, Gupta RK, Morton DL: Clinical significance of tumor associated immune complexes in sarcoma patients. *Proc Amer Soc Clin Oncol* 10:349, 1991.
91. Gupta RK, Bauer RL, Morton DL: Clinical significance of a 90kDa glycoprotein tumor-associated antigen containing immune complexes in melanoma patients with Stage I disease. *Proc Amer Soc Clin Oncol* 10:37, 1991.
92. Gupta RK, Morton DL: Tumor associated antigen specific immune complexes in sera of patients with breast carcinoma as a prognostic indicator of recurrence. *Proc Amer Soc Clin Oncol* 12:113, 1993.
93. Morton D, Nizze A, Hoon D, Foshag L, Famatiga E, Gupta R, Irie R, Ramming K: Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine. *Proc Amer Soc Clin Oncol* 12:391, 1993.
94. Singer FR, Gupta RK, Morton DL: Antibodies to sarcoma associated antigens are present in sera of patients with Paget's disease of bone. Program of the 16th Annual Meeting of the American Society for Bone and Mineral Research, pp S229, 1994.
95. Jones RC, Guenther JM, Gupta RK, Morton DL: Adverse effect of IgG antibody response on the survival of patients receiving melanoma cell vaccine. 48th Annual Cancer Symposium of the Society of Surgical Oncology, 1995.
96. Jones RC, Gupta RK, Morton DL: Clinical significance of a glycoprotein tumor-associated antigen-specific immune complex in patients with ocular melanoma. *Proc Am Assoc Cancer Res* 36:640, 1995.
97. Gupta RK, Morton DL: Detection of a 90kD glycoprotein tumor-associated antigen specific immune complexes in sera of patients with breast cancer. *The XXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine, (Submitted)*, 1995.
98. Gupta RK, Brosman SA, Morton DL: Tumor-antigen specific immune complexes in sera of prostate cancer patients. *5th International Congress on Hormone and Cancer, (Submitted)*.